Gamco Investors INC. ET AL Lowers Stock Position in Heska Corp (NASDAQ:HSKA)

Share on StockTwits

Gamco Investors INC. ET AL lessened its holdings in Heska Corp (NASDAQ:HSKA) by 8.8% during the third quarter, Holdings Channel.com reports. The firm owned 31,000 shares of the medical research company’s stock after selling 3,000 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Heska were worth $2,197,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Gabelli Funds LLC boosted its holdings in Heska by 4.4% in the 2nd quarter. Gabelli Funds LLC now owns 4,700 shares of the medical research company’s stock valued at $400,000 after purchasing an additional 200 shares in the last quarter. State of Tennessee Treasury Department boosted its holdings in Heska by 8.5% in the 3rd quarter. State of Tennessee Treasury Department now owns 2,770 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 218 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Heska by 2.7% during the 2nd quarter. Arizona State Retirement System now owns 10,821 shares of the medical research company’s stock valued at $922,000 after acquiring an additional 285 shares during the period. Swiss National Bank lifted its position in shares of Heska by 2.3% during the 2nd quarter. Swiss National Bank now owns 13,400 shares of the medical research company’s stock valued at $1,141,000 after acquiring an additional 300 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in shares of Heska by 6.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,794 shares of the medical research company’s stock valued at $408,000 after acquiring an additional 309 shares during the period. 92.57% of the stock is currently owned by institutional investors.

A number of equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Heska from a “hold” rating to a “buy” rating in a research report on Thursday, October 31st. Canaccord Genuity reiterated a “buy” rating and set a $105.00 price target (up from $75.00) on shares of Heska in a research report on Wednesday. Piper Jaffray Companies assumed coverage on shares of Heska in a research report on Wednesday, September 18th. They set a “neutral” rating and a $68.00 price target for the company. ValuEngine upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of Heska from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. Seven analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Heska currently has a consensus rating of “Hold” and an average price target of $85.75.

Shares of Heska stock traded up $0.93 during trading on Friday, hitting $91.58. 74,900 shares of the company were exchanged, compared to its average volume of 89,917. Heska Corp has a fifty-two week low of $62.47 and a fifty-two week high of $105.00. The firm has a 50 day moving average price of $75.74 and a 200 day moving average price of $76.31. The stock has a market capitalization of $735.22 million, a price-to-earnings ratio of 64.49 and a beta of 1.06. The company has a quick ratio of 2.05, a current ratio of 8.52 and a debt-to-equity ratio of 0.31.

Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Heska had a net margin of 3.15% and a return on equity of 3.17%. The company had revenue of $31.24 million during the quarter, compared to analysts’ expectations of $30.44 million. Analysts predict that Heska Corp will post 0.04 earnings per share for the current year.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Further Reading: What are Institutional Investors?

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.